Extensive-stage Small-cell Lung Cancer trials recruiting in Illinois

All Extensive-stage Small-cell Lung Cancer trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Illinois: Chicago, Decatur, Rockford
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
  NCT05068232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Niles
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
  NCT06598306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago